natgillin/translations-raw huggingface dataset:
Infection*, Bacterial infections*, Viral infections*, Sepsis (inc septic shock)*, Bronchopneumonia, Herpes virus infection*, Meningoencephalitis herpetic#, Bacteraemia (inc staphylococcal), Hordeolum, Influenza, Cellulitis, Device related infection, Skin infection*, Ear infection*, Staphylococcal infection, Tooth infection* 
Občasni okužba*, bakterijske okužbe*, virusne okužbe*, sepsa (vključno s septičnim šokom)*, bronhopnevmonija, okužba s herpesvirusom*, herpetični meningoencefalitis#, bakteriemija (vključno s stafilokokno), hordeol, gripa, celulitis, z uporabo katetra povezana okužba, okužba kože*, ušesne okužbe*, okužba s stafilokoki, okužbe zob*
Treatment with Bortezomib Accord can very commonly cause a decrease in the numbers of red and white blood cells and platelets in your blood. 
- težave s kašljem in dihanjem ali tiščanje v prsih Zdravljenje z zdravilom Bortezomib Accord lahko zelo pogosto povzroči zmanjšanje števila rdečih in belih krvnih celic ter krvnih ploščic.
Bortezomib Accord was administered only in Blocks 1 and 2 to avoid potential overlapping toxicities with coadministered drugs in Block 3. 
Bolniki so prejeli bortezomib le v 1. in 2. sklopu zdravljenja, da so se izognili prekrivanju toksičnih učinkov z drugimi, sočasno danimi zdravili v 3.
This study met its primary objective of non-inferiority for response rate (CR+PR) after 4 cycles of single agent bortezomib for both the subcutaneous and intravenous routes, 42% in both groups. 
V študiji je bil dosežen primarni cilj, 42% stopnja odziva (CR+PR) po 4 krogih zdravljenja z bortezomibom v monoterapiji pri subkutani in intravenski uporabi.
A drug-drug interaction study assessing the effect of rifampicin, a potent CYP3A4 inducer, on the pharmacokinetics of bortezomib (injected intravenously), showed a mean bortezomib AUC reduction of 45% based on data from 6 patients. 
Študija medsebojnega delovanja zdravil, ki je ocenjevala učinek rifampicina, močnega induktorjaencima CYP3A4, na farmakokinetiko bortezomiba (danega intravensko), je na osnovi podatkov 6 bolnikov pokazala povprečno zmanjšanje AUC bortezomiba za 45%.
There is no evidence to suggest that dose adjustments are necessary in patients over 65 years of age with multiple myeloma or with mental cell lymphona. 
Dokazov, ki bi potrdili, da je pri bolnikih z diseminiranim plazmocitomom ali limfomom plaščnih celic, starejših od 65 let potrebna prilagoditev odmerka, ni.
How to store Bortezomib Accord Contents of the pack and other information 
Shranjevanje zdravila Bortezomib Accord Vsebina pakiranja in dodatne informacije
Hypertension*, Hypotension*, Orthostatic hypotension 
Pogosti hipertenzija*, hipotnzija*, ortostatska hipotenzija
In the Phase III study patients who received bortezomib subcutaneously compared to intravenous administration had 13% lower overall incidence of treatment emergent adverse reactions that were Grade 3 or higher in toxicity, and a 5% lower incidence of discontinuation of bortezomib. 
V študiji faze III so imeli bolniki, ki so prejemali bortezomib subkutano za 13% manjšo celokupno incidenco neželenih učinkov zaradi uporabe zdravila, s stopnjo toksičnosti 3 ali več in za 5% manjšo pogostnost prekinitve zdravljenja v primerjavi z bolniki, ki so prejemali bortezomib intravensko.
Bortezomib therapy should be withheld when the platelet count is < 25,000/µl or, in the case of combination with melphalan and prednisone, when the platelet count is ≤ 30,000/µl (see section 4.2). 
Zdravljenje je treba prekiniti, kadar se bolnik zdravi z bortezomibom in je število trombocitov < 25.000/µl, ali če se bolnik zdravi z bortezomibom v kombinaciji z melfalanom in prednizolonom in je število trombocitov < 30.000/µl (glejte poglavje 4.2).
CR+nCR+PR 121 (38) 
CR + nCR 41 (13)b 5 (2)b CR+ nCR + PR 121 (38)b
Clinical efficacy in previously untreated mantle cell lymphoma (MCL) Study LYM-3002 was a Phase III, randomised, open-label study comparing the efficacy and safety of the combination of bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (BzR-CAP; n=243) to that of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP; n=244) in adult patients with previously untreated MCL (Stage II, III or IV). 
V randomizirani, odprti študiji faze III, LYM-3002, so pri odraslih bolnikih s predhodno nezdravljenim MCL (stopnje II, III ali IV) primerjali učinkovitost in varnost bortezomiba v kombinaciji z rituksimabom, ciklofosfamidom, doksorubicinom, vinkristinom in prednizonom (BzR-CAP; n=243) z zdravljenjem z rituksimabom, ciklofosfamidom, doksorubicinom, vinkristinom in prednizonom (R-CHOP; n=244).
• Bortezomib Accord 3.5 mg can be administered both intravenously and subcutaneously, while Bortezomib Accord 1 mg can be administered only intravenously 
• Zdravilo Bortezomib Accord 3,5 mg se daje intravensko in subkutano, medtem ko se lahko Bortezomib Accord 1 mg daje samo intravensko.
• to remind that patients receiving Bortezomib Accord in combination with thalidomide should adhere to the pregnancy prevention programme of thalidomide, with reference to the SmPC of thalidomide for additional information. 
• Bolnike, ki prejemajo zdravilo Bortezomib Accord v kombinaciji s talidomidom je treba opozoriti, da morajo upoštevati program preprečevanja nosečnosti kot je predpisan za talidomid,
You should not use Bortezomib Accord if you are pregnant, unless clearly necessary. 
Nosečnost in dojenje Če ste noseči zdravila Bortezomib Accord ne smete prejeti, razen, če je nujno potrebno.
In patients with MCL (study LYM-3002), there was a higher incidence (56.7% versus 5.8%) of Grade ≥ 3 thrombocytopenia in the bortezomib treatment group (BzR-CAP) as compared to the non-bortezomib treatment group (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]). 
Pri bolnikih z MCL (študija LYM-3002) je bila pojavnost trombocitopenije stopnje 3 ali več v skupini, ki je prejemala bortezomib (BzR-CAP), večja (56,7 % proti 5,8 %), v primerjavi s skupino, ki bortezomiba ni prejemala (rituksimab, ciklofosfamid, doksorubicin, vinkristin in prednizon [R-CHOP]).
Bz= Bortezomib Accord; Dx=dexamethasone; T=thalidomide a Thalidomide dose is increased to 100 mg from week 3 of Cycle 1 only if 50 mg is tolerated and to 200 mg from cycle 2 
Bz=Bortezomib Accord; Dx=deksametazon; T=talidomid a V 3. tednu 1. kroga se lahko odmerek talidomida poveča na 100 mg samo, če bolnik dobro prenaša odmerek 50 mg, in na 200 mg v 2. krogu, če bolnik dobro prenaša odmerek 100 mg.
• advice on method of administration for both intravenous and subcutaneous use, including the need to rotate injection sites for subcutaneous use 
• Navodila za dajanje zdravila intravensko in subkutano in da je pri subkutani uporabi potrebno menjati mesta injiciranja.
In studies in patients with relapsed multiple myeloma treated with bortezomib and in patients with previously untreated MCL treated with bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (BzR-CAP), one of the most common haematologic toxicity was transient thrombocytopenia. 
V študijah zdravljenja z bortezomibom pri bolnikih s ponovitvijo diseminiranega plazmocitoma in pri bolnikih z nezdravljenim MCL, v kombinaciji z rituksimabom, ciklofosfamidom, doksorubicinom in prednizonom (BzR-CAP), je bil najpogostejši toksični učinek na hematološki sistem prehodna trombocitopenija.
Intent to Treat Populationb n=74 
Populacija bolnikov, ki naj bi jo zdravili (TTP)b n=74
Once the symptoms of the toxicity have resolved, bortezomib treatment may be re-initiated at a 25% reduced dose (1.3 mg/m2 reduced to 1.0 mg/m2; 1.0 mg/m2 reduced to 0.7 mg/m2). 
Ko znaki toksičnosti minejo, lahko zdravljenje z bortezomibom ponovno uvedete, vendar s 25% manjšim odmerkom (1,3 mg/m2 zmanjšano na 1,0 mg/m2;
ASEPTIC TECHNIQUE MUST BE STRICTLY OBSERVED THROUGHOUT HANDLING OF BORTEZOMIB ACCORD SINCE NO PRESERVATIVE IS PRESENT. 
Pri delu z zdravilom Bortezomib Accord morate ves čas strogo upoštevati aseptično pripravo, ker zdravilo ne vsebuje konzervansov.
A drug-drug interaction study assessing the effect of ketoconazole, a potent CYP3A4 inhibitor, on the pharmacokinetics of bortezomib (injected intravenously), showed a mean bortezomib AUC increase of 35% (CI90% [1.032 to 1.772]) based on data from 12 patients. 
CYP3A4, na famakokinetiko bortezomiba (danega intravensko), je na osnovi podatkov 12 bolnikov pokazala povprečen dvig AUC bortezomiba za 35% (CI90% (1.032 do 1.772)).
Bortezomib Accord is given intravenously or subcutaneously on days 1, 4, 8 and 11, followed by a ‘rest period' without treatment. 
Zdravilo Bortezomib Accord boste prejeli intravensko na 1., 4., 8. in 11. dan, temu pa bo sledil premor brez zdravljenja.
Uncommon Cardiovascular disorder (inc cardiogenic shock) Vascular disorders Common 
Občasni srčnožilne bolezni (vključno s kardiogenim šokom)
222 patients with relapsed/refractory multiple myeloma, who were randomised in a 2:1 ratio to receive 1.3 mg/m2 of bortezomib by either the subcutaneous or intravenous route for 8 cycles. 
V študijo je bilo vključenih 222 bolnikov z relapsom/diseminiranim plazmocitomom, odpornim na zdravljenje, randomiziranih 2:1 na bortezomib, z odmerkom1,3 mg/m2 telesne površine subkutano ali intravensko 8 krogov zdravljenja.
If you have not been treated before for multiple myeloma, and you are not suitable for blood stem cell transplantation you will receive Bortezomib Accord together with two other medicines; melphalan and prednisone. 
Če vam diseminiranega plazmocitoma še niso zdravili in presaditev krvotvornih matičnih celic za vas ni primerna, vam bodo zdravilo Bortezomib Accord injicirali v veno skupaj z zdraviloma melfalan in prednizolon.
• different reconstitution requirements for intravenous or subcutaneous use 
• Informacijo o različnem postopku rekonstitucije pri intravenskem ali subkutani uporabi zdravila.
When Bortezomib Accord is given together with pegylated liposomal doxorubicin, you will receive Bortezomib Accord intravenously or subcutaneously as a 21-day treatment cycle and pegylated liposomal doxorubicin 30 mg/m2 is given on day 4 of the Bortezomib Accord 21-day treatment cycle as an intravenous infusion after the Bortezomib Accord injection. 
Če boste prejeli zdravilo Bortezomib Accord skupaj s pegiliranim liposomskim doksorubicinom, vam bodo zdravilo Bortezomib Accord injicirali v veno ali v podkožje v 21-dnevnem krogu zdravljenja in pegilirani liposomski doksorubicin v odmerku 30 mg/m2 v obliki enourne intravenske infuzije na
Bortezomib Accord will be administered by a health care professional experienced in the use of cytotoxic medicines. 
Zdravilo Bortezomib Accord vam bo injiciral zdravstveni delavec z izkušnjami z uporabo citotoksičnih zdravil.
Also included are adverse drug reactions identified in the BzR-CAP arm that were considered by investigators to have at least a possible or probable causal relationship to bortezomib based on historical data in the multiple myeloma studies. 
Vključeni so tudi neželeni učinki, ugotovljeni v skupini BzR-CAP, ki so na osnovi podatkov študij diseminiranega plazmocitoma in po mnenju raziskovalcev najmanj verjetno ali možno povezani z uporabo bortezomiba.
Vision abnormal* 
Pogosti nenormalen vid *
Patients with previously treated light-chain (AL) Amyloidosis An open label non randomised Phase I/II study was conducted to determine the safety and efficacy of bortezomib in patients with previously treated light-chain (AL) Amyloidosis. 
V odprti, ne-randomizirani študiji faze I/II so ugotavljali varnost in učinkovitost bortezomiba pri bolnikih, s predhodno zdravljeno AL amiloidozo.
You might receive up to 8 cycles (24 weeks). 
Prejeli boste lahko do 8 krogov zdravljenja (24 tednov).
The CR rate in first-relapsed T-cell ALL patients (n = 22) was 68% (95% CI: 45, 86) and the 4-month event free survival rate was 67% (95% CI: 42, 83). 
(n = 22) je bil 68 % (95% CI: 45, 86), delež 4-mesečnega preživetja bolnikov brez dogodkov pa 67 % (95% CI: 42, 83).
Hepatotoxicity (inc liver disorder), Hepatitis*, Cholestasis 
Občasni hepatotoksičnost (vključno z boleznimi jeter), hepatitis*, holestaza
If you have not been treated before for multiple myeloma, and you are suitable for blood stem cell transplantation you will receive Bortezomib Accord intravenously or subcutaneously together with the medicines dexamethasone, or dexamethasone and thalidomide, as induction treatment. 
Če pri vas diseminiranega plazmocitoma še niso zdravili in je presaditev krvotvornih matičnih celic za vas primerna, boste kot uvajalno zdravljenje prejeli zdravilo Bortezomib Accord v veno ali v podkožje v kombinaciji z deksametazonom ali z deksametazonom in talidomidom.
Erythema multiforme, Urticaria, Acute febrile neutrophilic dermatosis, Toxic skin eruption, Toxic epidermal necrolysis#, Stevens-Johnson syndrome#, Dermatitis*, Hair disorder*, Petechiae, Ecchymosis, Skin lesion, Purpura, Skin mass*, Psoriasis, Hyperhidrosis, Night sweats, Decubitus ulcer#, Acne*, Blister*, Pigmentation disorder* 
Občasni multiformni eritem, urtikarija, akutna febrilna nevtrofilna dermatoza, toksični kožni izpuščaj, toksična epidermalna nekroliza#, Stevens-Johnsonov sindrom#, dermatitis*, bolezni las*, petehije, ehimoze, spremembe na koži, purpura, kožna masa*, luskavica, hiperhidroza, nočno znojenje, dekubitusna razjeda#, akne*, mehurček*, motnje pigmentacije*
Patients who experience bortezomib-related neuropathic pain and/or peripheral neuropathy are to be managed as presented in Table 1 (see section 4.4). 
Nevropatična bolečina in/ali periferna nevropatija Bolnike, ki imajo nevropatično bolečino in/ali periferno nevropatijo v povezavi z jemanjem bortezomiba, zdravite v skladu s preglednico 1 (glejte poglavje 4.4).
e Mantel-Haenszel estimate of the common odds ratio for stratified tables is used, with IPI risk and stage of disease as stratification factors. 
e Uporabljena je Mantel-Haenszelova ocena razmerja verjetnosti za stratificirane preglednice, skupaj s stratifikacijskima dejavnikoma
Bortezomib Accord is used for the treatment of mantle cell lymphoma (a type of cancer affecting the lymph nodes) in patients 18 years or older in combination with the medicines rituximab, cyclophosphamide, doxorubicin and prednisone, for patients whose disease has not been previously treated and for whom blood stem cell transplantation is unsuitable. 
Zdravilo Bortezomib Accord se uporablja za zdravljenje limfoma plaščnih celic (redka oblika raka, ki prizadene bezgavke) pri bolnikih, starih 18 let in več, v kombinaciji z rituksimabom, ciklofosfamidom, doksorubicinom in prednizonom, pri bolnikih, pri katerih bolezni še nismo zdravili in pri katerih presaditev krvotvornih matičnih celic ni primerna.
3.5 mg/vial 
VIALA 3,5 mg
Pegylated liposomal doxorubicin is administered at 30 mg/m2 on day 4 of the Bortezomib Accord treatment cycle as a 1 hour intravenous infusion administered after the Bortezomib Accord injection. 
Pegilirani liposomski doksorubicin se daje v obliki 1-urne intravenske infuzije v odmerku 30 mg/m² na 4. dan kroga zdravljenja, po injiciranju zdravila Bortezomib Accord.
Patients in the BzDx group received four 21 day cycles, each consisting of bortezomib (1.3 mg/m2 administered intravenously twice weekly on days 1, 4, 8, and 11), and oral dexamethasone (40 mg/day on days 1 to 4 and days 9 to 12, in Cycles 1 and 2, and on days 1 to 4 in Cycles 3 and 4). 
V vsakem krogu so prejeli bortezomib (1,3 mg/m2 intravensko dvakrat na teden na 1., 4., 8. in 11. dan) in deksametazon (40 mg/dan, peroralno, 1. do 4. in 9. do 12. dan v 1. in 2. krogu in 1. do 4. dan v 3. in 4. krogu).
How to use Bortezomib Accord 
Kako uporabljati zdravilo Bortezomib Accord
- in combination with the medicines dexamethasone or dexamethasone together with thalidomide, for patients whose disease has not been previously treated and before receiving high-dose chemotherapy with blood stem cell transplantation (induction treatment). 
- v kombinaciji z deksametazonom ali z deksametazonom in talidomidom, pri bolnikih, pri katerih bolezni še nismo zdravili in pred kemoterapijo v visokih odmerkih in presaditvijo krvotvornih matičnih celic (uvajalno zdravljenje).
Musculoskeletal and connective tissue disorders 
Bolezni mišično skeletnega sistema, vezivnega tkiva in kosti
• Increased heartbeat, high blood pressure, sweating, 
• občutek omotičnosti • zvišan srčni utrip, visok krvni tlak, potenje
Bortezomib treatment must be withheld at the onset of any Grade 3 non-haematological or any Grade 4 haematological toxicities, excluding neuropathy as discussed below (see also section 4.4). 
3. stopnje ali katerekoli hematološke toksičnosti 4. stopnje, z izjemo nevropatije, kot je opisano v nadaljevanju (glejte tudi poglavje 4.4).
A median of 6 cycles was received by patients in both treatment arms with 14% of subjects in the BzR-CAP group and 17% of patients in the R-CHOP group receiving 2 additional cycles. 
14% preiskovancev iz skupine BzR-CAP in 17% bolnikov iz skupine R-CHOP je prejelo 2 dodatna kroga zdravljenja.
• shingles (localised including around the eyes or spread across the body) 
• opazite pasasti izpuščaj (lokaliziran, vključno s področjem okoli oči ali razširjen po telesu),
Transfusion reaction, Fractures*, Rigors*, Face injury, Joint injury*, Burns, Laceration, Procedural pain, Radiation injuries* 
Redki reakcije na transfuzijo, zlomi*, okorelost*, poškodbe obraza, poškodbe sklepov*, opekline#, raztrganine, bolečina pri posegu, poškodbe pri obsevanju*
In addition, when bortezomib is given in combination with other chemotherapeutic medicinal products, appropriate dose reductions for these medicinal products should be considered in the event of toxicities, according to the recommendations in the respective Summary of Product Characteristics. 
Kadar dajemo bortezomib v kombinaciji z drugimi kemoterapevtiki je v primeru pojava toksičnosti potrebno razmisliti o zmanjšanju odmerka teh zdravil, skladno z njihovimi Povzetki glavnih značilnosti zdravil.
Cardiac fibrillation (inc atrial), Arrhythmia*, Cardiac failure (inc left and right ventricular)*, Myocardial ischaemia, Ventricular dysfunction* 
Pogosti fibrilacija srca (vključno z atrijsko), aritmija*, srčno popuščanje (vključno s popuščanjem levega in desnega prekata)*, ishemija miokarda, moteno delovanje prekatov*
Bortezomib treatment is commonly associated with orthostatic/postural hypotension. 
Zdravljenje z bortezomibom je pogosto povezano z ortostatsko hipotenzijo oz. posturalno hipotenzijo.
≥ 750 cells/μL and a platelet count ≥ 25,000 cells/μL. 
ANC ≥ 750 celic/μl in število trombocitov ≥ 25.000 celic/μl.
A statistically significant survival benefit in favour of the Bz+M+P treatment group was observed (HR=0.695; p=0.00043) despite subsequent therapies including bortezomib-based regimens. 
Pri bolnikih v skupini Bz+M+P so opazili statistično značilno izboljšanje preživetja (HR (Hazard Ratio - razmerje tveganja)=0,695; p=0,00043),
VDDx=vincristine, doxorubicin, dexamethasone; BzDx= bortezomib, dexamethasone; TDx=thalidomide, dexamethasone; BzTDx= bortezomib, thalidomide, dexamethasone; PN=peripheral neuropathy Note: Peripheral neuropathy included the preferred terms: neuropathy peripheral, peripheral motor neuropathy, peripheral sensory neuropathy, and polyneuropathy. 
VDDx=vinkristin, doksorubicin, deksametazon; BzDx=bortezomib, deksametazon; TDx=talidomid, deksametazon; BzTDx=bortezomib, talidomid, deksametazon; PN=periferna nevropatija
Sepsis (inc septic shock)*, Herpes zoster (inc disseminated & ophthalmic), Herpes virus infection*, Bacterial infections*, Upper/lower respiratory tract infection*, Fungal infection*, Herpes simplex* 
Zelo pogosti pljučnica* Pogosti sepsa (vključno s septičnim šokom)*, herpes zoster (vključno z diseminiranim in očesnim), okužba s herpes virusom, bakterijske okužbe *, okužba zgornjih/spodnjih dihal*, glivična okužba *, herpes simplex*
The incidence of herpes zoster among patients in the Bz+M+P treatment group was 17% for patients not administered antiviral prophylaxis compared to 3% for patients administered antiviral prophylaxis. 
V skupini, zdravljeni z Bz+M+P, je pri 17% bolnikov, ki niso prejemali protivirusnih zdravil, prišlo do reaktivacije virusa herpes zoster, pri bolnikih, ki so prejemali protivirusna zdravila, pa je prišlo do reaktivacije virusa pri 3% bolnikov.
BzR-CAP=Bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone; R-CHOP= rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; PN=peripheral neuropathy Peripheral neuropathy included the preferred terms: peripheral sensory neuropathy, neuropathy peripheral, peripheral motor neuropathy, and peripheral sensorimotor neuropathy 
BzR-CAP=bortezomib, rituksimab, ciklofosfamid, doksorubicin in prednizon; R-CHOP= rituksimab, ciklofosfamid, doksorubicin, vinkristin in prednizon; PN=periferna nevropatija
The protocol allowed patients to receive dexamethasone if they had had a less than optimal response to bortezomib alone. 
V skladu s protokolom so bolniki lahko prejeli deksametazon, če ni bilo pričakovanega odziva na zdravljenje z bortezomibom v monoterapiji.
In addition, when Bortezomib Accord is given in combination with other chemotherapeutic medicinal products, appropriate dose reductions for these products should be considered in the event of toxicities according to the recommendations in the Summary of Product Characteristics. 
Kadar dajemo zdravilo Bortezomib Accord v kombinaciji z drugimi kemoterapevtiki je v primeru pojava toksičnosti potrebno razmisliti o zmanjšanju odmerka teh zdravil, skladno z njihovimi Povzetki glavnih značilnosti zdravil.
Therefore, caution should be used during handling and preparation of Bortezomib Accord. 
Spošni previdnostni ukrepi Bortezomib je citotoksičen, zato je potrebna previdnost med njegovo pripravo in ravnanjem z zdravilom Bortezomib Accord.
Blood gases abnormal*, Electrocardiogram abnormalities (inc QT prolongation)*, International normalised ratio abnormal*, Gastric pH decreased, Platelet aggregation increased, Troponin I increased, Virus identification and serology*, Urine analysis abnormal* 
nenormalno mednarodno umerjeno razmerje*, znižan pH v želodcu, zvečana agregacija trombocitov, zvišana koncentracija troponina I, identifikacija in serologija virusov*, nenormalni izvidi analize urina*
CI=confidence interval; CR=complete response; nCR=near complete response; ITT=intent to treat; RR=response rate; Bz= bortezomib; BzDx= bortezomib, dexamethasone; VDDx=vincristine, doxorubicin, dexamethasone; VGPR=very good partial response; PR=partial response; OR=odds ratio. 
CI=interval zaupanja; CR=popoln odgovor; nCR=skoraj popoln odgovor; ITT=populacija, ki so jo nameravali zdraviti; RR=stopnja odgovora; Bz=bortezomib; BzDx=bortezomib in deksametazon; VDDx=vinkristin, doksorubicin in deksametazon; VGPR=zelo dober delni odgovor; PR=delni odgovor; OR=razmerje verjetnosti.
As a result of a pre-planned interim analysis, the dexamethasone arm was halted at the recommendation of the data monitoring committee and all patients randomised to dexamethasone were then offered bortezomib, regardless of disease status. 
Kot rezultat predhodno načrtovane vmesne analize, so del preskušanja, v katerem so bolniki dobivali deksametazon zaključili v skladu s priporočilom komisije, ki je spremljala podatke.
Autologous stem cell transplants were received by 198 (82%) patients and 208 (87%) patients in the VDDx and BzDx groups respectively; the majority of patients underwent one single transplant procedure. 
Avtologno presaditev krvotvornih matičnih celic so opravili pri 198 (82%) bolnikih v skupini BzDx in
Day 1, 2, 3, 4 Day 8, 9, 10, 11Cycles 2 to 4 
Dx 40 mg dan 1, 2, 3, 4 dan 8, 9, 10, 11krogi 2 do 4b
At least 6 months after prior therapy, bortezomib was started at the last tolerated dose of 1.3 mg/m2 (n=93) or ≤ 1.0 mg/m2 (n=37) and given on days 1, 4, 8 and 11 
Po najmanj 6 mesecih po predhodnem zdravljenju, so bortezomib uvedli v odmerku, ki ga je bolnik pri predhodnem zdravljenju še prenašal, 1,3 mg/m2 (n=93) ali ≤ 1,0 mg/m2 (n=37).
Bortezomib Accord therapy should be withheld until symptoms of the toxicity have resolved to Grade 1 or baseline. 
Zdravljenje z zdravilom Bortezomib Accord je treba prekiniti, dokler se simptomi toksičnosti ne povrnejo na 1. stopnjo ali stanje pred začetkom zdravljenja.